Construction of an auxiliary scoring model for myelosuppression in patients with lung cancer chemotherapy based on random forest algorithm

To construct an auxiliary scoring model for myelosuppression in patients with lung cancer undergoing chemotherapy based on a random forest algorithm, and to evaluate the predictive performance of the model. Patients with lung cancer who received chemotherapy in Shanxi Province Cancer Hospital from J...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:American journal of translational research Jg. 15; H. 6; S. 4155
Hauptverfasser: Dong, Yingjun, Hu, Changqing, Liu, Jun, Lv, Huifang
Format: Journal Article
Sprache:Englisch
Veröffentlicht: United States 01.01.2023
Schlagworte:
ISSN:1943-8141, 1943-8141
Online-Zugang:Weitere Angaben
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Abstract To construct an auxiliary scoring model for myelosuppression in patients with lung cancer undergoing chemotherapy based on a random forest algorithm, and to evaluate the predictive performance of the model. Patients with lung cancer who received chemotherapy in Shanxi Province Cancer Hospital from January 2019 to January 2022 were retrospectively selected as research subjects, and their general demographic information, disease-related indicators, and laboratory test results before chemotherapy were collected. Patients were divided into a training set (136 cases) and a validation set (68 cases) in a ratio of 2:1. R software was used to establish a scoring model of myelosuppression in lung cancer patients in the training set, and the receiver operating characteristic curve, accuracy, sensitivity, and balanced F-score were used in the two data sets to evaluate the predictive performance of the model. Among the 204 lung cancer patients enrolled, 75 patients developed myelosuppression during the follow-up period after chemotherapy, with an incidence of 36.76%. The factors in the constructed random forest model were ranked in order of age (23.233), bone metastasis (21.704), chemotherapy course (19.259), Alb (13.833), and gender (11.471) according to the mean decrease accuracy. The areas under the curve of the model in the training and validation sets were 0.878 and 0.885, respectively (all < 0.05). The predictive accuracy of the validated model was 82.35%, the sensitivity and specificity were 84.00% and 81.40%, respectively, and the balanced F-score was 77.78% (all < 0.05). The risk assessment model for the occurrence of myelosuppression in patients with lung cancer chemotherapy based on a random forest algorithm can provide a reference for the accurate identification of high-risk patients.
AbstractList To construct an auxiliary scoring model for myelosuppression in patients with lung cancer undergoing chemotherapy based on a random forest algorithm, and to evaluate the predictive performance of the model.OBJECTIVETo construct an auxiliary scoring model for myelosuppression in patients with lung cancer undergoing chemotherapy based on a random forest algorithm, and to evaluate the predictive performance of the model.Patients with lung cancer who received chemotherapy in Shanxi Province Cancer Hospital from January 2019 to January 2022 were retrospectively selected as research subjects, and their general demographic information, disease-related indicators, and laboratory test results before chemotherapy were collected. Patients were divided into a training set (136 cases) and a validation set (68 cases) in a ratio of 2:1. R software was used to establish a scoring model of myelosuppression in lung cancer patients in the training set, and the receiver operating characteristic curve, accuracy, sensitivity, and balanced F-score were used in the two data sets to evaluate the predictive performance of the model.METHODSPatients with lung cancer who received chemotherapy in Shanxi Province Cancer Hospital from January 2019 to January 2022 were retrospectively selected as research subjects, and their general demographic information, disease-related indicators, and laboratory test results before chemotherapy were collected. Patients were divided into a training set (136 cases) and a validation set (68 cases) in a ratio of 2:1. R software was used to establish a scoring model of myelosuppression in lung cancer patients in the training set, and the receiver operating characteristic curve, accuracy, sensitivity, and balanced F-score were used in the two data sets to evaluate the predictive performance of the model.Among the 204 lung cancer patients enrolled, 75 patients developed myelosuppression during the follow-up period after chemotherapy, with an incidence of 36.76%. The factors in the constructed random forest model were ranked in order of age (23.233), bone metastasis (21.704), chemotherapy course (19.259), Alb (13.833), and gender (11.471) according to the mean decrease accuracy. The areas under the curve of the model in the training and validation sets were 0.878 and 0.885, respectively (all P < 0.05). The predictive accuracy of the validated model was 82.35%, the sensitivity and specificity were 84.00% and 81.40%, respectively, and the balanced F-score was 77.78% (all P < 0.05).RESULTSAmong the 204 lung cancer patients enrolled, 75 patients developed myelosuppression during the follow-up period after chemotherapy, with an incidence of 36.76%. The factors in the constructed random forest model were ranked in order of age (23.233), bone metastasis (21.704), chemotherapy course (19.259), Alb (13.833), and gender (11.471) according to the mean decrease accuracy. The areas under the curve of the model in the training and validation sets were 0.878 and 0.885, respectively (all P < 0.05). The predictive accuracy of the validated model was 82.35%, the sensitivity and specificity were 84.00% and 81.40%, respectively, and the balanced F-score was 77.78% (all P < 0.05).The risk assessment model for the occurrence of myelosuppression in patients with lung cancer chemotherapy based on a random forest algorithm can provide a reference for the accurate identification of high-risk patients.CONCLUSIONThe risk assessment model for the occurrence of myelosuppression in patients with lung cancer chemotherapy based on a random forest algorithm can provide a reference for the accurate identification of high-risk patients.
To construct an auxiliary scoring model for myelosuppression in patients with lung cancer undergoing chemotherapy based on a random forest algorithm, and to evaluate the predictive performance of the model. Patients with lung cancer who received chemotherapy in Shanxi Province Cancer Hospital from January 2019 to January 2022 were retrospectively selected as research subjects, and their general demographic information, disease-related indicators, and laboratory test results before chemotherapy were collected. Patients were divided into a training set (136 cases) and a validation set (68 cases) in a ratio of 2:1. R software was used to establish a scoring model of myelosuppression in lung cancer patients in the training set, and the receiver operating characteristic curve, accuracy, sensitivity, and balanced F-score were used in the two data sets to evaluate the predictive performance of the model. Among the 204 lung cancer patients enrolled, 75 patients developed myelosuppression during the follow-up period after chemotherapy, with an incidence of 36.76%. The factors in the constructed random forest model were ranked in order of age (23.233), bone metastasis (21.704), chemotherapy course (19.259), Alb (13.833), and gender (11.471) according to the mean decrease accuracy. The areas under the curve of the model in the training and validation sets were 0.878 and 0.885, respectively (all < 0.05). The predictive accuracy of the validated model was 82.35%, the sensitivity and specificity were 84.00% and 81.40%, respectively, and the balanced F-score was 77.78% (all < 0.05). The risk assessment model for the occurrence of myelosuppression in patients with lung cancer chemotherapy based on a random forest algorithm can provide a reference for the accurate identification of high-risk patients.
Author Hu, Changqing
Lv, Huifang
Liu, Jun
Dong, Yingjun
Author_xml – sequence: 1
  givenname: Yingjun
  surname: Dong
  fullname: Dong, Yingjun
  organization: Intensive Care Unit, Shanxi Provincial Cancer Hospital/Shanxi Hospital Affiliated to Cancer Hospital, Chinese Academy of Medical Sciences/Cancer Hospital Affiliated to Shanxi Medical University Taiyuan 030013, Shanxi, China
– sequence: 2
  givenname: Changqing
  surname: Hu
  fullname: Hu, Changqing
  organization: Department of Cardiology, Shanxi Provincial People's Hospital Taiyuan 030012, Shanxi, China
– sequence: 3
  givenname: Jun
  surname: Liu
  fullname: Liu, Jun
  organization: The Fifth People's Hospital of Datong Datong 037056, Shanxi, China
– sequence: 4
  givenname: Huifang
  surname: Lv
  fullname: Lv, Huifang
  organization: Intensive Care Unit, Shanxi Provincial Cancer Hospital/Shanxi Hospital Affiliated to Cancer Hospital, Chinese Academy of Medical Sciences/Cancer Hospital Affiliated to Shanxi Medical University Taiyuan 030013, Shanxi, China
BackLink https://www.ncbi.nlm.nih.gov/pubmed/37434857$$D View this record in MEDLINE/PubMed
BookMark eNpNkMtKAzEYhYNUbK2-gmTpZmCSTCbJUoo3KLjR9ZAmmU4klzHJoH0Fn9opVnB1_sX5zn84l2ARYjBnYIVEQyqOGrT4dy_BZc7vdd1S0eILsCSsIQ2nbAW-NzHkkiZVbAww9lAGKKcv66xMB5hVTDbsoY_aONjHBP3BuJincUwm5yNiAxxlsSaUDD9tGaCbZkDJoEyCajA-lsEkOR7gTmaj4YwkGXT0xziTC5RuPz8pg78C57102VyfdA3eHu5fN0_V9uXxeXO3rUYkWKkYZRgbjHqkBe93WiBC67ZVSjZtK3lPOJGM6wZhgnpNW9XUWtQa15QxIajBa3D7mzum-DHNFTpvszLOyWDilDvMSYsF55TM1puTddp5o7sxWT_v0v3th38A8qRx7Q
ContentType Journal Article
Copyright AJTR Copyright © 2023.
Copyright_xml – notice: AJTR Copyright © 2023.
DBID NPM
7X8
DatabaseName PubMed
MEDLINE - Academic
DatabaseTitle PubMed
MEDLINE - Academic
DatabaseTitleList MEDLINE - Academic
PubMed
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: 7X8
  name: MEDLINE - Academic
  url: https://search.proquest.com/medline
  sourceTypes: Aggregation Database
DeliveryMethod no_fulltext_linktorsrc
Discipline Medicine
EISSN 1943-8141
ExternalDocumentID 37434857
Genre Journal Article
GroupedDBID ---
23M
2WC
53G
ADBBV
AEGXH
AENEX
ALMA_UNASSIGNED_HOLDINGS
BAWUL
C1A
DIK
F5P
GX1
HYE
NPM
OK1
RNS
RPM
TR2
7X8
OVT
ID FETCH-LOGICAL-p197t-75722e21f1d98fbd9135066cca466a8f383a78d41231fd56c40d90d20577995e2
IEDL.DBID 7X8
ISICitedReferencesCount 5
ISICitedReferencesURI http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=001032073000015&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
ISSN 1943-8141
IngestDate Thu Jul 10 18:44:56 EDT 2025
Thu Apr 03 06:55:12 EDT 2025
IsPeerReviewed false
IsScholarly true
Issue 6
Keywords prediction model
random forest
chemotherapy
myelosuppression
Lung cancer
Language English
License AJTR Copyright © 2023.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-p197t-75722e21f1d98fbd9135066cca466a8f383a78d41231fd56c40d90d20577995e2
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
PMID 37434857
PQID 2836298853
PQPubID 23479
ParticipantIDs proquest_miscellaneous_2836298853
pubmed_primary_37434857
PublicationCentury 2000
PublicationDate 2023-01-01
PublicationDateYYYYMMDD 2023-01-01
PublicationDate_xml – month: 01
  year: 2023
  text: 2023-01-01
  day: 01
PublicationDecade 2020
PublicationPlace United States
PublicationPlace_xml – name: United States
PublicationTitle American journal of translational research
PublicationTitleAlternate Am J Transl Res
PublicationYear 2023
SSID ssj0065962
Score 2.3206286
Snippet To construct an auxiliary scoring model for myelosuppression in patients with lung cancer undergoing chemotherapy based on a random forest algorithm, and to...
SourceID proquest
pubmed
SourceType Aggregation Database
Index Database
StartPage 4155
Title Construction of an auxiliary scoring model for myelosuppression in patients with lung cancer chemotherapy based on random forest algorithm
URI https://www.ncbi.nlm.nih.gov/pubmed/37434857
https://www.proquest.com/docview/2836298853
Volume 15
WOSCitedRecordID wos001032073000015&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
hasFullText
inHoldings 1
isFullTextHit
isPrint
link http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1LT8MwDI6AIcSF92O8ZCSuFWuaNskJIQTiwKYdAO02pU0Ck7p2rBtif4FfjdNlcEJC4tJLlT5ix_5iO_4IuUi5jalJbCCVtAFLIxUIwUSQ8EwnzFph6j4Fzw-80xG9nuz6gFvlyyoXNrE21LrMXIz8Et1gQqVA73I1egsca5TLrnoKjWXSiBDKuIXJe99ZhMQxy9RZZRa5UFf4O4qsvcnd5n-_Y4tseBwJ13PBb5MlU-yQtbbPlO-ST8fEuegNC6UFVYCafgzygRrPoMrqujuoeXAAcSsMZyYvq-nI18UWMCjA91ytwAVrIUezAJlTkjGgpIf-6NYMnCPUgEPQ7ely6B6HvwMqf8GXTF6He-Tp7vbx5j7wvAvBKJR8EvCYU2poaEMthU21DKMYkQnKmiWJEhY3tYoLzdDphVbHScZaWrY0Rejn2ssZuk9WirIwhwSMtGnaitOWsbg1MlFqQrzPqIlNZmlkmuR8Mct91GuXrFCFKadV_2eem-RgLqr-aN6Aox8h7GEi5kd_GH1M1h1D_DxqckIaFle1OSWr2ftkUI3PaoXBa6fb_gLkWtIp
linkProvider ProQuest
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Construction+of+an+auxiliary+scoring+model+for+myelosuppression+in+patients+with+lung+cancer+chemotherapy+based+on+random+forest+algorithm&rft.jtitle=American+journal+of+translational+research&rft.au=Dong%2C+Yingjun&rft.au=Hu%2C+Changqing&rft.au=Liu%2C+Jun&rft.au=Lv%2C+Huifang&rft.date=2023-01-01&rft.issn=1943-8141&rft.eissn=1943-8141&rft.volume=15&rft.issue=6&rft.spage=4155&rft_id=info%3Apmid%2F37434857&rft_id=info%3Apmid%2F37434857&rft.externalDocID=37434857
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1943-8141&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1943-8141&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1943-8141&client=summon